ABUS - Arbutus Biopharma Corp - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ABUS is currently covered by 3 analysts with an average price target of $4.92. This is a potential upside of $1.59 (47.75%) from yesterday's end of day stock price of $3.33.

Arbutus Biopharma Corp's activity chart (see below) currently has 62 price targets and 73 ratings on display. The stock rating distribution of ABUS is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 40.11% with an average time for these price targets to be met of 82.1 days.

Highest price target for ABUS is $5, Lowest price target is $5, average price target is $4.92.

Most recent stock forecast was given by ED ARCE from HC WAINWRIGHT on 21-Jan-2025. First documented stock forecast 22-Sep-2014.

Currently out of the existing stock ratings of ABUS, 25 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$5

$1.67 (50.15%)

$5

11 days ago
(21-Jan-2025)

0/17 (0%)

$1.79 (55.76%)

Buy

$5

$1.67 (50.15%)

$4

2 months 12 days ago
(20-Nov-2024)

4/11 (36.36%)

$1.51 (43.27%)

136

Buy

$5

$1.67 (50.15%)

$4

5 months 30 days ago
(02-Aug-2024)

2/6 (33.33%)

$1.26 (33.69%)

256

Buy

$5

$2.08 (71.23%)

2 years 11 months 30 days ago
(02-Feb-2022)

0/1 (0%)

$2.11 (73.01%)

Buy

$7

3 years 7 months 4 days ago
(28-Jun-2021)

0/4 (0%)

$3.7 (112.12%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ABUS (Arbutus Biopharma Corp) average time for price targets to be met?

On average it took 82.1 days on average for the stock forecasts to be realized with a an average price target met ratio 40.11

Which analyst has the current highest performing score on ABUS (Arbutus Biopharma Corp) with a proven track record?

ROBERT DRISCOLL

Which analyst has the most public recommendations on ABUS (Arbutus Biopharma Corp)?

Robert Driscoll works at WEDBUSH and has 14 price targets and 9 ratings on ABUS

Which analyst is the currently most bullish on ABUS (Arbutus Biopharma Corp)?

Jason Kolbert with highest potential upside - $10.67

Which analyst is the currently most reserved on ABUS (Arbutus Biopharma Corp)?

Liisa Bayko with lowest potential downside - -$0

Arbutus Biopharma Corp in the News

Does AI Really Make Moderna Stock (NASDAQ:MRNA) a Buy?

Moderna (NASDAQ:MRNA) stock has collapsed from its all-time high. However, the company is once again on the move — in a good way. The stock is up 68% over the past six months, with partnerships around artificial intelligence (AI) and positive cancer trial data garnering investor interest. Personally, though, I’m still unconvinced that these developments...

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline.In HBV003, 31% of participants with screening HBsAg level of ≤200 IU/mL had >1 log HBsAg reductions. VTP-300 was generally well-tolerated in both trials. OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?